Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Identifies New Mineralised Trends and Refines Targeting with Magnetic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexicon Pharmaceuticals Inc LXRX

Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of... see more

Recent & Breaking News (NDAQ:LXRX)

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2025

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

GlobeNewswire May 19, 2025

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire May 13, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

GlobeNewswire May 6, 2025

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

GlobeNewswire May 6, 2025

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

GlobeNewswire March 28, 2025

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire March 7, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire March 6, 2025

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

GlobeNewswire March 4, 2025

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire March 3, 2025

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire March 2, 2025

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

GlobeNewswire February 18, 2025

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

GlobeNewswire January 21, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer

GlobeNewswire January 2, 2025

Lexicon Announces Receipt of Complete Response Letter for Zynquista(TM) (sotagliflozin)

GlobeNewswire December 20, 2024

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswire November 26, 2024

Lexicon Pharmaceuticals to Participate in December Investor Conferences

GlobeNewswire November 25, 2024

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

GlobeNewswire November 22, 2024

Lexicon Appoints Ivan H. Cheung to Board of Directors

GlobeNewswire November 20, 2024